Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC1 | Q13547 | 1/20 | 0.35 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.35 |
| ▸ | PDPK1 | O15530 | 1/20 | 0.35 |
| ▸ | DPP4 | P27487 | 15/20 | 0.33 |
| ▸ | RORC | P51449 | 1/20 | 0.33 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.32 |
| ▸ | FAP | Q12884 | 1/20 | 0.32 |
| ▸ | DPP8 | Q6V1X1 | 1/20 | 0.32 |
| ▸ | DPP9 | Q86TI2 | 1/20 | 0.32 |
| ▸ | DPP7 | Q9UHL4 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL749408 | 1.00 | HDAC1 (0.35) | HDAC1HDAC8PDPK1DPP4RORC | |
| SCHEMBL749410 | 1.00 | HDAC1 (0.35) | HDAC1HDAC8PDPK1DPP4RORC | |
| SCHEMBL30136575 | 1.00 | HDAC1 (0.35) | HDAC1HDAC8PDPK1DPP4RORC | |
| SCHEMBL13780810 | 0.84 | DPP4 (0.36) | HDAC1HDAC8DPP4RORCFAP | |
| SCHEMBL5643743 | 0.81 | MAPK8 (0.46) | PDPK1 | |
| SCHEMBL5643739 | 0.81 | MAPK8 (0.46) | PDPK1 | |
| SCHEMBL5643735 | 0.81 | MAPK8 (0.46) | PDPK1 | |
| SCHEMBL2861837 | 0.80 | DPP4 (0.41) | HDAC1HDAC8DPP4RORCDPP8 | |
| SCHEMBL742800 | 0.80 | DPP4 (0.41) | HDAC1HDAC8DPP4RORCDPP8 | |
| SCHEMBL29738305 | 0.80 | DPP4 (0.41) | HDAC1HDAC8DPP4RORCDPP8 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2010131025-A1 | SITAGLIPTIN SYNTHESIS | GENERICS [UK] LIMITED (GB) | 2010-11-18 | — | — | WO | claimed |
| US-8846916-B2 | Sitagliptin synthesis | GENERICS [UK] LIMITED (GB) | 2014-09-30 | — | — | US | disclosed |
| US-20120108598-A1 | SITAGLIPTIN SYNTHESIS | MYLAN INDIA PRIVATE LIMITED (IN) | 2012-05-03 | — | — | US | disclosed |
| EP-2430025-A1 | SITAGLIPTIN SYNTHESIS | Generics [UK] Limited (GB) | 2012-03-21 | — | — | EP | disclosed |
| WO-2010131025-A1 | SITAGLIPTIN SYNTHESIS | GENERICS [UK] LIMITED (GB) | 2010-11-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120108598-A1 | SITAGLIPTIN SYNTHESIS | DPP4, DPP7, DPP3 | HDAC1 3285/4885HDAC8 3312/4885PDPK1 2846/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.